Immunology and Microbiology
Urinary Tract
100%
Uropathogenic Escherichia Coli
90%
Staphylococcus Aureus
58%
Porcine Model
46%
Escherichia coli
46%
Severe Acute Respiratory Syndrome Coronavirus 2
42%
Biofilm
31%
COVID-19
25%
Neutralization
22%
Omicron Coronavirus Variant
14%
Virus
13%
Filamentation
13%
Fimbria
12%
Animal Experiment
12%
Infectious Agent
12%
Micturition
10%
Antimicrobial Resistance
9%
Monoclonal Antibody
9%
Inoculum
9%
Peptides
9%
Booster Dose
8%
Cytotoxicity
8%
Low Drug Dose
8%
Macrophage
8%
Colony-Forming Unit
7%
Abdominal Pressure
7%
Mediator
7%
Urine Sampling
7%
Viral Load
7%
Medline
7%
Bacterial Count
7%
Complement Lectin Pathway
7%
Complement Activation
7%
Dynamics
7%
Antibacterial Activity
6%
Immunocompromised Patient
6%
Thioridazine
6%
Breed
6%
Raman Spectroscopy
6%
Aspergillus
6%
4 [3 (1h Tetrazol 5 Yl) 8 Coumarinyloxy]butyric Acid
6%
Biomechanics
6%
Matrix Protein
6%
Alpha-2-Macroglobulin
6%
Bladder Emptying
6%
Bone Structure
6%
Bladder Mucosa
6%
Antibiotic Sensitivity
6%
Lectin Pathway
6%
Bactericidal Activity
6%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
31%
Staphylococcus Aureus
28%
Infection
25%
Antiinfective Agent
21%
Prodrug
19%
Escherichia coli
14%
Thioridazine
12%
Dicloxacillin
12%
Pleuromutilin
12%
Urinary Tract Infection
12%
Antibiotics
12%
Effusion
10%
P-Glycoprotein
9%
Antibacterial Activity
9%
CYP3A4
8%
Immunocompromised Patient
8%
Uropathogenic Escherichia Coli
7%
Porcine Model
7%
Drug Delivery System
7%
Digestant
7%
Bloodstream Infection
7%
Antivirus Agent
6%
Surgical Infection
6%
Graft Infection
6%
Aspergillus
6%
Fucoidan
6%
RNA 23S
6%
Pleuromutilin Antibiotic Agent
6%
Enkephalin[2 Dextro Alanine 5 Dextro Leucine]
6%
Staphylococcal Infection
6%
Malignant Neoplasm
6%
Ovine Model
6%
Hyperplasia
6%
Polypeptide Antibiotic Agent
6%
Laminaria
6%
Povidone
6%
1 Vinyl 2 Pyrrolidinone
6%
Glycoprotein
6%
Absorption-Distribution-Metabolism-Excretion Toxicity
6%
Blood-Brain Barrier
6%
Pharmacokinetics
6%
Plasma Protein Binding
6%
Bioavailability
6%
Cytotoxicity
6%
Gram Positive Infection
6%
Messenger RNA
6%
Monotherapy
6%
Remdesivir
6%
Peptidomimetics
6%
Fenugreek
6%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
25%
Bladder
16%
Urinary Tract Infection
15%
Urinary Tract
14%
COVID-19
13%
Immunocompromised Patient
12%
Infection
11%
Ex Vivo
8%
Urinary System
8%
Virus
8%
Residual Urine
7%
Microtrauma
7%
Residual Volume
7%
Drug Delivery System
6%
Mitomycin
6%
Surgical Infection
6%
Catheterization
6%
Virus Shedding
6%
Alpha 2 Macroglobulin
6%
Mediator
6%
Diabetic Nephropathy
6%
Mesangial Cell
6%
Kidney Tissue
6%
In Vitro
5%
Micturition
5%
